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PCRAbstract Background: Apolipoprotein E (apo E) gene polymorphism was found to be associated
with coronary artery disease in several studies.
In this investigation, we aimed to study the association between apo E gene polymorphism and
acute coronary syndrome in Egyptian population.
Subjects and methods: The study included 200 patients with acute coronary syndrome (myocardial
infarction and unstable angina), and 100 healthy controls. Anthropometric, clinical and lipid profile
parameters were evaluated. Apo E genotyping was carried out using sequence-specific-primer
(SSP)-PCR methodology.
Results: Є3/4 genotype frequency was higher in the patients than in the controls (P< 0.05),
while Є2/3 genotype frequency was elevated in the controls than in the patients (P< 0.05). In
addition, the frequency of Є4 isoform was higher in the patients compared to the controls
(P< 0.001). Patients with Є3/4 and Є4/4 genotypes had significantly higher total cholesterol and
low density lipoprotein cholesterol, and lower triglyceride levels than those with Є3/3 genotype.
No significant differences in apo E genotype distribution were found between myocardial infarction
and unstable angina patients.
Conclusion: Apo E gene polymorphism had a role in acute coronary syndrome, possibly through
affecting plasma lipid parameters.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Morbidities related to atherosclerosis, such as acute coronary
syndromes (ACSs) including unstable angina and myocardialinfarction are leading causes of mortality, and approximately
seven million patients die annually due to coronary artery
diseases [1]. Genetic factors were found to play a role in the
pathogenesis of coronary artery disease [2]. Apolipoprotein E
(apo E) is a 34-kDa protein found associated with several
classes of plasma lipoproteins with a primary function in
cholesterol and lipid transport [3]. Apo E is expressed in most
cells of the body and the gene coding for apo E is located on
the long arm of chromosome 19 (q13.32) [4]. Its gene contains
Table 1 Primers used for SSP-PCR.
Primer Sequence Products
Primer-1
(forward)
50-CGG ACA TGG AGG ACG
TGT-30
173 bp
Primer-2
(reverse)
50-CTG GTA CAC TGC CAG
GCG-30
Primer-3
(reverse)
50-CTG GTA CAC TGC CAG
GCA-30
173 bp
Primer-4
(forward)
50-CGG ACA TGG AGG ACG
TGC-30
Control primers:
Forward 50-TGC CAA GTG GAG CAC
CCAA-30
785 and
1598 bp
Reverse 50-GCA TCT TGC TCT GTG
CAG AT-30
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phisms (SNPs) at positions +2059 (T/C), located in the codon
that codes for amino acid 112 and +2197 (C/T), that codes for
amino acid 2196 of the apo E protein. Allelic variation within
the Apo E gene has been shown to account for as much as 7%
of the interindividual variability in low density lipoprotein
cholesterol (LDL-C) and total cholesterol (TC). Multiple
studies in human populations have demonstrated the associa-
tions of the Є4 isoform with increased LDL-C and of the Є2
isoform with decreased LDL-C levels [5]. The common
isoforms of apo E are; Є2 (2059-T/2197-T), Є3 (2059-T/2197-C),
and Є4 (2059-C/2059-C). The presence of T at position 2059
(2059-T) of the gene defines a cysteine at position 112 (Cys
112), whereas 2059-C defines an arginine for the same position
(Arg 112). Similarly, 2197-C on the gene defines an arginine at
position 158 (Arg 158), whereas 2197-T codes for cysteine for
the same position (Cys 158) [6]. Apo E polymorphisms have been
found to be associated with many lipid-related diseases and with
circulating markers of inflammation like C-reactive protein [7–10].
The aim of the present investigation was to study the
association of apo E gene polymorphism with acute coronary
syndromes in Egyptian population.
2. Subjects and methods
2.1. Study subjects
The study included 200 patients with acute coronary
syndromes (100 acute myocardial infarction patients and 100
unstable angina patients), enrolled from the coronary unit of
Sohag University Hospital. 100 healthy subjects, matched for
age and sex and resided in the same geographical region, with
no previous history of coronary artery disease or atherosclero-
sis served as controls. Acute coronary syndromes (ACSs) have
been defined as unstable angina or myocardial infarction with
or without S-T segment elevation. Patients with unstable ang-
ina had ischemic chest pain within the preceding 48 hours with
transiently depressed S-T segment and/or inverted T-wave.
The diagnosis of myocardial infarction was done by the pres-
ence of two of the following: the electrocardiographic finding
of S-T segment elevation of 1 mm in two or more successive
leads, typical chest pain longer than 20 min’ duration and an
elevation in serial cardiac markers. Confirmation of the diag-
nosis by the presence of hypokinetic and akinetic segments
at angiography [11]. The inclusion criteria for the patients
were; no history of liver or renal disease and absence of non-
atherogenic occlusion. The inclusion criteria for the controls
were; no history of atherosclerosis, vascular disease, diabetes
mellitus, renal or liver disease and normal ECG patterns.
Written informed consents were obtained from all the enrollees
and the study was carried out in accordance with the guidelines
of the ethics committee of Sohag Faculty of Medicine.
2.2. Anthropometric parameters and blood pressure
measurements
Body weight and height were measured in the morning while
the participants were unclothed and without shoes. BMI was
calculated as body weight (in kg) divided by height2 (in m2).
Body mass index (BMI) was defined as the weight divided by
the square of the height (kg/m2). According to WHO, normalrange BMI is from 18.50 to 24.99 kg/m2, overweightP 25 kg/m2
and obeseP 30 kg/m2 (WHO expert consultation, 2004) [12].
Blood pressure was read from the left arm while subjects
remained seated. An average of 3 measurements was recorded.
Hypertension was considered if the systolic BPP 140 mmHg
or the diastolic BPP 90 mmHg or if the patient reported BP
reducing medication use [13].
2.3. Blood collection and laboratory analysis
Approximately 5 ml venous blood samples were collected from
the participants after an overnight fasting on EDTA tubes.
The samples were centrifuged at 3000 rpm for 15 min and
the buffy coat was used for DNA extraction using QIAamp
kit supplied by Qiagen (USA). Plasma was used for the estima-
tion of lipid parameters and blood glucose. Total cholesterol
(TC), high density lipoprotein cholesterol (HDL-C), triglyc-
erides (TG) and fasting glucose were determined using an
enzymatic method on Cobas C 311 analyzer (Roche diagnos-
tics, Germany). Low-density lipoprotein-cholesterol (LDL-C)
was calculated using the Friedewald formula. The diagnosis
of type 2 diabetes mellitus was done according to the American
Diabetes Association Criteria [14], by presence of one or more
of the following criteria: [1] treatment with hypoglycemic
agents; [2] two diagnostic tests showing high blood glucose
levels (fasting plasma glucoseP 126 mg/dL and/or 2-h plasma
glucoseP 200 mg/dL during an oral glucose tolerance test).
2.4. Genotyping
We used an Apo E haplotype sequence-specific-primer (SSP)-
PCR methodology that identifies in three PCR reactions the
allelic haplotypes that determine the three main Apo E
isoforms according to Pantelidis et al. [6]. Two forward and
two reverse primers Table.1 were used for three primer mix
reactions as follows; For Є2, the primer mix consists of primers
1 and 3, for Є3, the primer mix consists of primers 1 and 2, and
for Є4, the primer mix consists of primers 2 and 4. For each
reaction mixture, a pair of control primers was added, it ampli-
fies two regions of chromosome 6 in the HLA-DR locus, to
verify PCR amplification in the absence of haplotype specific
amplification in each PCR reaction. The PCR cycling condi-
tions were as follows: initial denaturation for 1 min at 96 C;
Figure 1a Lane 1; 100 bp ladder, lanes 2, 3 and 4 represent
Є3/4 genotype and lanes 5, 6 and 7 represent Є4/4 genotype.
Figure 1b Lane 1; 100 bp ladder, lanes 2, 3 and 4 represent
Є3/3genotype and lanes 5, 6 and 7 represent Є2/3 genotype.
Table 2 Demographic, clinical and laboratory data of the
study groups.
Characteristic Controls, n = 100 Patients, n = 200
Age (years) 54 ± 33 53 ± 5.07
BMI (kg/m2) 25.3 ± 1.8 26.4 ± 3.2
Male gender, n (%) 35 (70) 140 (70)
Hypertension, n (%) – 120 (60)
T2DM, n (%) – 80 (40)
TC (mg/dL) 186.9 ± 12.4 208.6 ± 47.7***
HDL-C (mg/dL) 38.9 ± 3.5 32.3 ± 7.8***
TG (mg/dL) 109 ± 29.4 139.6 ± 29.3***
LDL-C (mg/dL) 101.8 ± 14.9 174 ± 66.9***
*** P< 0.0001.
Table 3 Genotype and isoform distribution in the cases and contro
Genotype Controls, n= 100
Є2/2, n (%) 2 (2)
Є2/3, n (%) 20 (20)
Є2/4, n (%) 1 (1)
Є3/3, n (%) 70 (70)
Є3/4, n (%) 6 (6)
Є4/4, n (%) 1 (1)
Є2, n (%) 25 (12.5)
Є3, n (%) 166 (83)
Є4, n (%) 9 (4.5)
* P< 0.05.
** P< 0.001.
Apolipoprotein E gene polymorphism 101followed by 5 cycles of 20 s at 96 C, 45 s at 70 C, and 25 s at
72 C; 21 cycles of 25 s at 96 C, 50 s at 65 C, and 30 s
at 72 C; 4 cycles of 30 s at 96 C, 60 s at 55 C, and 120 s at
72 C. The PCR products were analyzed by electrophoresis
on 2% agarose gel stained with ethidium bromide. For all
PCR reactions (Є2, Є3, and Є4), the presence of a 173 bp band
indicated the presence of the specific Apo E haplotype. For the
control primer pair, two products were obtained of 785 and
1598 bp (may be absent), Figs. 1a and b.
2.5. Statistical analysis
Data were expressed as mean ± SD or number and percent.
Genotype distribution was tested for deviation from HWE
(Hardy–Weinberg equilibrium) by x2 analysis. Odd ratio with
95% confidence interval was calculated to compare the geno-
type frequencies in patients and controls. Continuous data
were compared using Mann–Whitney and ANOVA tests and
categorical data were compared using Chi-square test. A
two-tailed value of P< 0.05 was considered statistically signif-
icant. All statistical calculations were performed using the
computer program SPSS (Statistical Package for the
Social Science; SPSS, Chicago, IL, version 16 for Microsoft
Windows, USA).
3. Results
Our results showed no significant differences between the study
groups regarding age, sex or BMI, while significant differences
were found in plasma lipids and the presence of hypertension
and T2DM, (Table 2). The genotype distribution was in
accordance with HWE for both patients and controls. The
most frequent genotype was Є3/3 (70% in the controls and
62% in the patients). Є3/4 genotype frequency was signifi-
cantly elevated in the patients than in the controls
(P< 0.05), while Є2/3 genotype frequency was significantly
higher in the controls than in the patients (P< 0.05). Є4
isoform was found more frequently in patients compared to
controls (P< 0.001), (Table 3). Patients with Є3/4 and Є4/4
genotypes had significantly higher TC and LDL-C and lower
TG levels than those with Є3/3 genotype and patients with
Є2/2, Є2/3, Є2/4 genotypes had lower LDL-C than Є3/3
genotype patients, (Table 4). No significant differences in
apo E genotype distribution were found between myocardial
infarction and unstable angina patients, (Table 4).ls.
Patients, n= 200 OR (95% CI)
2 (1) 0.49 (0.07–3.6)
21 (10.5) 0.47 (0.24–0.9)*
7 (3.5) 3.5 (0.44–59.6)
124 (62) 0.7 (0.4–1.17)
42 (21) 4 (1.7–10.17)*
4 (2) 2 (0.2–18.3)
32 (8) 0.6 (0.35–1)
311 (77.75) 0.7 (0.46–1)
57 (14.25) 3.5 (1.7–7.3)**
Table 4 Clinical characteristics in acute coronary syndrome patients according to genotype.
Є2/2, Є2/3, Є2/4, n= 30 Є3/3, n= 124 Є3/4, Є4/4, n= 46
BMI 25.3 ± 2.5 25.97 ± 2.6 27.2 ± 4*
Hypertension, n (%) 17 (57) 73 (59) 30 (65)
T2DM, n (%) 10 (33) 50 (40) 20 (43)
TC (mg/dL) 191 ± 19.5 191.6 ± 20.9 246.5 ± 66.6***
HDL-C (mg/dL) 34.4 ± 8 32.8 ± 7.9 31 ± 7.3
TG (mg/dL) 207.9 ± 61 196 ± 59 137.3 ± 31.5***
LDL-C (mg/dL) 132.8 ± 18.3 153.2 ± 52.5 188 ± 68.9***
Clinical presentation
Unstable angina/MI 14/16 60/62 22/26
Patients were subdivided according to the isoforms (Є2, Є3 or Є4), due to the low frequency of Є2/2, Є2/4 and Є4/4 genotypes.
* P< 0.05.
*** P< 0.0001.
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Apo E gene polymorphism was found to be associated with
variations in lipoprotein concentration and coronary artery
disease [5]. In this study, Є3/3 genotype was the most frequent
genotype found in the study population, a finding presented by
other investigators [5,15]. Є3/4 genotype was more in the
patients, while Є2/3 genotype was more frequent in the control
group, in addition Є4 isoform frequency was significantly
higher in the patients than in the controls. In accordance with
our results, a meta-analysis by Xu et al. showed that MI
patients had an increased frequency of Є4 and Є3/4 genotype,
while Є2/3 genotype was more frequent in the controls [15].
However, a study of the association between apo E genotype
and risk of coronary artery disease in White and African
Americans showed no association between apo E alleles and
coronary artery disease [5].
Our study showed that the Є2 isoform was associated with
lower plasma levels of LDL-C and the Є4 isoform with higher
levels, a result similar to those obtained in previous studies
[5,10,16]. Regarding the elevated triglyceride levels in Є2
carriers, our results were similar to those obtained by other
investigators [17–18]. The elevated triglyceride levels in Є2
carriers may be due to the impaired hepatic clearance of
triglyceride rich lipoproteins as apo E2 is defective in binding
to the LDL receptor [3].
The association between Є4 isoform and acute coronary
syndrome can be explained based on the association between
Є4 isoform and elevated plasma total cholesterol and LDL-C
levels. Also, in a previous study Є4 isoform carriers were found
to have high carotid artery intima-media thickness measures
compared to other isoform carriers [5]. Elevated LDL-C levels
are associated with a high risk of coronary artery disease and
LDL oxidation could induce atherosclerosis [19].
Apo E plays an important role in the metabolism of choles-
terol and triglycerides, by binding to its receptors mediating
the clearance of chylomicron and remnant particles from
plasma. In addition apo E was found to be associated with
inflammatory markers and coagulation factors [20]. The three
common isoforms; Є2, Є3 and Є4, have different receptor-
binding abilities and could yield different circulating levels of
cholesterol and triglycerides. Compared with Є3 homozygotes,
carriers of the Є2 isoform have lower circulating cholesterol
levels, whereas carriers of the Є4 isoform appear to havehigher plasma levels of total and low-density lipoprotein
cholesterol. According to the previous finding, we could
explain the association between Є 4 isoform and acute
coronary syndrome [15]. In conclusion, our study revealed
an association between apo E gene polymorphism and acute
coronary syndrome in Egyptian population, however, further
studies are needed to elucidate the relation between apo E
genotype, low density lipoprotein particle size and apo E
protein levels.
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